Wuppertal, Germany

Axel Bouchon

USPTO Granted Patents = 4 


Average Co-Inventor Count = 5.1

ph-index = 3

Forward Citations = 83(Granted Patents)


Location History:

  • Cologne, DE (2009)
  • Köln, DE (2010)
  • Wuppertal, DE (2012 - 2015)

Company Filing History:


Years Active: 2009-2015

Loading Chart...
Loading Chart...
4 patents (USPTO):

Title: Axel Bouchon: Innovator in Myeloid Cell Research

Introduction

Axel Bouchon is a prominent inventor based in Wuppertal, Germany. He has contributed significantly to the field of immunology with a focus on myeloid cells. With two patents to his name, Bouchon's work centers around novel activating receptors known as TREM (triggering receptor expressed on myeloid cells).

Latest Patents

Bouchon's latest patents detail the innovative use of TREM-1 and TREM-2, which are members of the Ig super-family expressed on human myeloid cells. TREM-1 is a transmembrane glycoprotein selectively found on blood neutrophils and a subset of monocytes, being upregulated by bacterial and fungal products. This receptor has promising applications in the treatment and diagnosis of various inflammatory diseases. On the other hand, TREM-2 is expressed on mast cells and peripheral dendritic cells. Stimulation of dendritic cells via TREM-2 is crucial for DC maturation, resistance to apoptosis, and promoting chemotaxis towards macrophage inflammatory protein 3-β. This indicates TREM-2's utility in modulating immune responses in autoimmune disorders and allergic conditions.

Career Highlights

Throughout his career, Axel Bouchon has worked with reputable companies such as Cosmo Research & Development S.p.A. and Novo Nordisk A/S. His expertise and innovative approach have led to significant advancements in the understanding of myeloid cell receptors.

Collaborations

Bouchon has collaborated with notable scientists in his field, including Marco Colonna and Rune Salbo. These partnerships have enhanced his research endeavors and contributed to the growth of knowledge regarding myeloid cell functions.

Conclusion

Axel Bouchon remains a key figure in immunology research, particularly in the study of myeloid cells and their receptors. His patents on TREM-1 and TREM-2 demonstrate his commitment to advancing medical science, with implications for diagnosing and treating various inflammatory and immune disorders. Through innovative research and effective collaborations, Bouchon continues to impact the scientific community positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…